Navigation Links
Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent

ROCKVILLE, Md., Jan. 26 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) today announced that it has received Official Notice of Allowance for its patent application, number 10/047,352, for Stable Neural Stem Cell Lines from the US Patent and Trade Office (USPTO). This patent covers the technology to immortalize any human neural stem cell, rendering its growth robust and long-lasting.


"We are pleased to have received the Notice of Allowance on this important technology," said President & CEO Richard Garr. "The technology behind this patent allows us to grow practically unlimited quantities of neural stem cells from all regions of the brain without regard to the natural mitotic (growth) limits of cells from a particular region. Equally important, this technology is a next-generation immortalization process that avoids the harmful effects of traditional immortalization methods, which have invariably resulted in uncontrolled growth. Our technology provides the necessary assurance that the cell lines are fully controlled and remain consistent trial-over-trial and year-after-year. This consistency is ultimately key to the commercialization of any cell products and greatly enhances our ability to deliver cell therapies for very prevalent diseases, such as stroke and traumatic brain injury. It will also enable, for the first time, systematic drug screening against many different kinds of normal human brain cells for new Central Nervous System (CNS) drugs, and stem cell-mediated protein delivery for neurologic diseases."

About the Technology

The newly patented method uses cMyc-ER, a recombinant fusion of two proteins normally present in cells, c-Myc, a human cell-cycle regulating protein, and estrogen receptor (ER), a human protein that is activated by estrogen. By transiently increasing the concentration of the c-Myc protein, a cell inserted with cMyc-ER is able to overcome the natural aging process inherent in the cell without losing any of its stem cell properties. The immortalized human neural stem cell can be grown for over 60 cell-doublings and is clonally expandable (that is starting from one cell).

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS). The Company filed an IND (Investigational New Drug) application with the FDA for ALS clinical trials in December, 2008, and has entered into a collaborative agreement with Albert-Ludwigs-University, in Freiburg, Germany, to develop clinical trials for Huntington's disease.

In pre-clinical work, the company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-KSB for the year ended December 31, 2007 and the quarterly report on form 10-Q for the period ended September 30, 2008.

SOURCE Neuralstem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Shares Accepted for Trading on Amex(R)
2. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
3. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
4. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
5. Neuralstem Sues StemCells, Inc. Over New Patent
6. Neuralstem Responds to New StemCells, Inc. Lawsuit
7. Neuralstem Fills Key Product Development Position
8. Neuralstem Reports Second Quarter Financial Results and Highlights
9. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
10. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
11. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
Post Your Comments:
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):